Progression Free Survival Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting progression free survival clinical trials across 4 countries. Studies span Not Applicable, Phase 2, Phase 3. Top locations include Boston, Massachusetts, United States, Guangzhou, China, Hangzhou, Zhejiang, China. Updated daily from ClinicalTrials.gov.


Progression Free Survival Trials at a Glance

7 actively recruiting trials for progression free survival are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Boston, Guangzhou, and Hangzhou. Lead sponsors running progression free survival studies include Johnson & Johnson Pharmaceutical Research & Development, Kaohsiung Medical University Chung-Ho Memorial Hospital, and First Affiliated Hospital of Zhejiang University.

Browse progression free survival trials by phase

Treatments under study

About Progression Free Survival Clinical Trials

Looking for clinical trials for Progression Free Survival? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Progression Free Survival trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Progression Free Survival clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting

Long-term Follow-up of Subjects Treated With CAR T Cells

AdultProgression Free SurvivalOverall Survival+4 more
Marcela V. Maus, M.D.,Ph.D.45 enrolled1 locationNCT05024175
Recruiting
Phase 2

Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy

Progression Free Survival
Kaohsiung Medical University Chung-Ho Memorial Hospital110 enrolled1 locationNCT06826092
Recruiting
Not Applicable

Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.

Progression Free SurvivalOverall SurvivalMaintenance
RenJi Hospital420 enrolled1 locationNCT05477797
Recruiting
Phase 3

Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer

Advanced CancerOlanzapineProgression Free Survival
Qinghai Red Cross Hospital230 enrolled1 locationNCT06338683
Recruiting
Not Applicable

A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial

Radiation ToxicityProgression Free SurvivalOverall Survival+2 more
Zhujiang Hospital88 enrolled1 locationNCT06215495
Recruiting
Phase 2

Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors

NeoadjuvantProgression Free SurvivalGastrointestinal Stromal Tumor
First Affiliated Hospital of Zhejiang University122 enrolled1 locationNCT04933669
Recruiting
Phase 3

A Phase 3 study comparing the combination of CAELYX and YONDELIS (the study drug) with CAELYX alone in subjects with advanced relapsed ovarian cancer who have previously had platinum based chemotherapy treatment (eg. Carboplatin/Cisplatin)

Advanced relapsed Ovarian Cancer - to prolong progression free survival
Johnson & Johnson Pharmaceutical Research & Development650 enrolled1 locationACTRN12607000169448